Gurugram caps rate of Covaxin at Rs 1410, Covishield at Rs 780, Sputnik V at Rs 1145 in private hospitals

Civil Surgeon Virender Yadav said that under the National Health Mission and Haryana's Mission Director, new orders have been issued after deciding the rates of all the three Covid vaccines Covaxin, Covishield and Sputnik V.

Published On 2021-06-26 04:00 GMT   |   Update On 2021-06-26 04:00 GMT

Gurugram: The Gurugram health department has announced a price cap for the administration of Covid-19 vaccines in private hospitals.Civil Surgeon Virender Yadav said that under the National Health Mission and Haryana's Mission Director, new orders have been issued after deciding the rates of all the three Covid vaccines Covaxin, Covishield and Sputnik V.Also Read: Form policy SOS to check...

Login or Register to read the full article

Gurugram: The Gurugram health department has announced a price cap for the administration of Covid-19 vaccines in private hospitals.

Civil Surgeon Virender Yadav said that under the National Health Mission and Haryana's Mission Director, new orders have been issued after deciding the rates of all the three Covid vaccines Covaxin, Covishield and Sputnik V.

Also Read: Form policy SOS to check fraud COVID vaccination drives: HC tells Maha Govt, BMC

"While the maximum price for Covaxin and Covishield has been fixed at Rs 1,410 and Rs 780 per dose respectively, Russia's Sputnik V vaccine will cost Rs 1,145 per dose in private hospitals," said Yadav.

He further said that a multi-disciplinary committee (MDC) has also been set up for taking up the complaints related to charging more than the prescribed fee.

Yadav has been appointed as the Chairman of the panel, while the other members include representative of the District Deputy Commissioner office and a representative of the Indian Medical Association.

"This committee will hear the complaints related to the overcharging of vaccines and an action will also be initiated against those hospitals," he added.

Also Read: Covaxin to Govt at Rs 150 per dose not sustainable in long run: Bharat Biotech

Tags:    
Article Source : IANS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News